Premarin/MPA 0.45 mg/1.5 mg
Phase 1Completed 0 watching 0 views this week๐ค Quiet
32
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postmenopause
Conditions
Postmenopause
Trial Timeline
May 1, 2007 โ Aug 1, 2007
NCT ID
NCT00472927About Premarin/MPA 0.45 mg/1.5 mg
Premarin/MPA 0.45 mg/1.5 mg is a phase 1 stage product being developed by Pfizer for Postmenopause. The current trial status is completed. This product is registered under clinical trial identifier NCT00472927. Target conditions include Postmenopause.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00472927 | Phase 1 | Completed |
Competing Products
16 competing products in Postmenopause